{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:38:57Z","timestamp":1773027537347,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.euroneuro.2014.05.004","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T21:15:11Z","timestamp":1400620511000},"page":"1248-1256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington\u05f3s disease"],"prefix":"10.1016","volume":"24","author":[{"given":"J.A.","family":"Bouwens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.M.","family":"Hubers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"van Duijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Cobbaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.A.C.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.C.","family":"van der Mast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.J.","family":"Giltay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2014.05.004_bib1","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.euroneuro.2014.05.004_bib2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1017\/S0007114511005460","article-title":"Dietary factors and low-grade inflammation in relation to overweight and obesity","volume":"106","author":"Calder","year":"2011","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib3","first-page":"219","article-title":"Behavioural changes in Huntington\u05f3s Disease","volume":"14","author":"Craufurd","year":"2001","journal-title":"Neuropsychiatry, Neuropsychol. Behav. Neurol."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2010.06.002","article-title":"Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naive psychotic sample","volume":"121","author":"Diaz","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib5","first-page":"45","article-title":"Tumour necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature","volume":"39","author":"Dofferhoff","year":"1991","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib6","doi-asserted-by":"crossref","first-page":"541259","DOI":"10.1155\/2013\/541259","article-title":"The role of the immune system in Huntington\u05f3s disease","volume":"2013","author":"Ellrichman","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","article-title":"Regional and cellular gene expression changes in human Huntington\u05f3s disease brain","volume":"15","author":"Hodges","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib9","series-title":"Cognitive Assessment for Clinicians","first-page":"118","article-title":"Initiation: verbal fluency tests","author":"Hodges","year":"2003"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib10","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/hmg\/2.12.2069","article-title":"Characterization and localization of the Huntington disease gene product","volume":"2","author":"Hoogeveen","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","article-title":"Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis","volume":"71","author":"Howren","year":"2009","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jad.2011.10.031","article-title":"Suicidality in Huntington\u05f3s disease","volume":"136","author":"Hubers","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington\u05f3s Disease Rating Scale: reliability and consistency. Huntington Study Group.","volume":"11","author":"Huntington Study Group","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/YIC.0b013e3283400cd3","article-title":"Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications","volume":"26","author":"Kim","year":"2011","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.genhosppsych.2007.11.005","article-title":"Behavioural problems in Huntington\u05f3s disease using the Problem Behaviours Assessment","volume":"30","author":"Kingma","year":"2008","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib16","first-page":"255","article-title":"The cascade of inflammatory cytokines regulating synthesis of acute phase proteins","volume":"13","author":"Koj","year":"1988","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1474-4422(05)70099-5","article-title":"Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis","volume":"4","author":"Kuo","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1515\/CCLM.1998.132","article-title":"Activated immune system in patients with Huntington\u05f3s disease","volume":"36","author":"Leblhuber","year":"1998","journal-title":"Clin. Chem. Lab Med."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/archgenpsychiatry.2011.1858","article-title":"Association of vascular factors with apathy in community-dwelling elderly individuals","volume":"69","author":"Ligthart","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/156720510790274392","article-title":"Serum albumin concentration and cognitive impairment","volume":"7","author":"Llewellyn","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib21","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/gps.2242","article-title":"Increased C-reactive protein is not associated with apathy: the Leiden 85-Plus Study","volume":"24","author":"Maas","year":"2009","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-0327(94)00106-J","article-title":"Total serum protein and serum protein fractions in depression: relationships to depressive symptoms and glucocorticoid activity","volume":"34","author":"Maes","year":"1995","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","volume":"66","author":"Meyer","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2014.05.004_bib24","first-page":"S1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/ageing\/afn102","article-title":"Albumin, haemoglobin, BMI and cognitive performance in older adults","volume":"37","author":"Ng","year":"2008","journal-title":"Age Ageing"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib26","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/YCO.0b013e32833f46c9","article-title":"Cardiovascular aspects of antipsychotics","volume":"23","author":"Raedler","year":"2010","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2012.03.041","article-title":"Irritability in Huntington\u05f3s disease","author":"Reedeker","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1176\/jnp.23.4.jnp434","article-title":"Incidence, course, and predictors of apathy in Huntington\u05f3s disease: a two-year prospective study","volume":"23","author":"Reedeker","year":"2011","journal-title":"J. Neuropsychiatry Clin. Neurosci"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1179\/1743132812Y.0000000073","article-title":"Oxidative stress and inflammation biomarkers in the blood of patients with Huntington\u05f3s disease","volume":"34","author":"Sanchez-Lopez","year":"2012","journal-title":"Neurol. Res."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib31","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.31.10.1333","article-title":"Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs","volume":"31","author":"Shoulson","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.29.1.1","article-title":"Huntington disease: clinical care and evaluation","volume":"29","author":"Shoulson","year":"1979","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JHD-130049","article-title":"A critical evaluation of inflammatory markers in Hungtinton\u05f3s disease plasma","volume":"2","author":"Silajdzic","year":"2013","journal-title":"J. Hungtinton\u05f3s Dis."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib34","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/WNR.0b013e32832e34ee","article-title":"Distinct neuroinflammatory profile in post-mortem human Huntington\u05f3s disease","volume":"20","author":"Silvestroni","year":"2009","journal-title":"Neuroreport"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib35","first-page":"83","article-title":"The Symbol Digit Modalities Test: a neuropsychologic test for economic screening of learning and other cerebral disorders","volume":"3","author":"Smith","year":"1968","journal-title":"Learn. Disord."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib36","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1037\/h0054651","article-title":"Studies of interference in serial verbal reactions","volume":"18","author":"Stroop","year":"1935","journal-title":"J. Exp. Psychol."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib37","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington\u05f3s disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib38","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington\u05f3s disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib40","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.4088\/JCP.v69n1116","article-title":"Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington\u05f3s disease compared with mutation-negative first-degree relatives","volume":"69","author":"van Duijn","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","article-title":"Psychopathology in verified Huntington\u05f3s disease gene carriers","volume":"19","author":"van Duijn","year":"2007","journal-title":"J. Neuropsychiatry Clin. Neurosci"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib42","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1176\/jnp.2010.22.3.287","article-title":"Correlates of apathy in Huntington\u05f3s disease","volume":"22","author":"van Duijn","year":"2010","journal-title":"J. Neuropsychiatry Clin. Neurosci"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(96)03010-7","article-title":"Lower total serum protein, albumin, and beta- and gamma-globulin in major and treatment-resistant depression: effects of antidepressant treatments","volume":"65","author":"van Hunsel","year":"1996","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib44","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jpsychires.2007.05.008","article-title":"Effect of CAG repeat length on psychiatric disorders in Huntington\u05f3s disease","volume":"42","author":"Vassos","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","article-title":"Pharmacologic approaches to the treatment of Huntington\u05f3s disease","volume":"27","author":"Venuto","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.brainres.2010.05.060","article-title":"Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state","volume":"1350","author":"Victoriano","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2014.05.004_bib47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u05f3s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.euroneuro.2014.05.004_bib48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/2013.jamapsychiatry.102","article-title":"Elevated C-reactive protein levels, psychological distress, and depression in 73,131 Individuals","volume":"70","author":"Wium-Andersen","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.05.004_bib49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-1781(00)00230-4","article-title":"Abnormal age-related changes of plasma antioxidant proteins in schizophrenia","volume":"97","author":"Yao","year":"2000","journal-title":"Psychiatry Res."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14001424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14001424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T17:48:25Z","timestamp":1597859305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X14001424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0924977X14001424"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.05.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington\u05f3s disease","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}